InnAccel Technologies

Medical Devices

CURRENT IMPACT

As on November 2022

500+

infants treated

150+

units installed in government health facilities in Assam

Geographical Focus
  • Assam, Chhattisgarh, Karnataka, Uttar Pradesh, Maharashtra, Rajasthan and Andhra Pradesh
Potential Impact
  • Reach

    66,000

    infants

Samridh support

SAMRIDH’s financial assistance is enabling InnAccel to scale-up the manufacturing and deployment of Saans, an easy-to-use, portable, neonatal Continuous Positive Air Pressure (CPAP) system. With this support, InnAccel has been able to hire a dedicated commercial and support team to drive the uptake of the device through private and public healthcare systems. In partnership with National Health Mission-Government of Assam, it is implementing state-wide deployment of the Saans devices in Special New-born Care Units(SNCUs) and Pediatric Intensive Care Units (PICU) of district hospitals and ambulances, and further providing a base to replicate the scale up across other states.

400,000

babies are born with respiratory distress each year in non-tertiary care settings in India[1]

150,000

of these infants die due to lack of respiratory support[2]

15.4
%

increase in child mortality in India due to direct and indirect effects of COVID-19[3]

Respiratory Distress Syndrome (RDS) is a common breathing disorder in premature babies in India, causing 150,000 deaths annually. The condition can be treated with Continuous Positive Air Pressure (CPAP). However, the majority of infants in India are born in primary or secondary care centers that do not have access to a Neonatal Intensive Care Unit (NICU) equipped to handle these medical emergencies soon after birth. The existing CPAP solutions require the use of neonatal intensive care unit (NICU) grade infrastructure, which makes them unusable during transport. As a result, about one-third of these RDS-related deaths occur while the infants are being transported to an NICU. These infant mortalities can be significantly reduced if CPAP therapy becomes accessible in lower-level heath care centers or during transport to NICUs.

[1] Jasbir Singh et al. Transport characteristics and predictors of mortality among neonates referred to a tertiary care centre in North India: a prospective observational study”, BMJ Online, July 2021

[2] Buch Pankaj, M., et al. “Status of Newborn Transport in Periphery and Risk Factors of Neonatal Mortality among Referred newborns.” Journal of Pharmaceutical and Biomedical Sciences 16.09 (2012):

[3] United Nations Children’s Fund, Direct and indirect effects of the COVID-19 pandemic and response in South Asia, UNICEF, Kathmandu, March 2021, p. 21

PORTABLE, INFRASTRUCTURE-INDEPENDENT, NEONATAL CPAP DEVICE

Saans is an easy-to-use, portable, neonatal/pediatric CPAP system that provides short-term breathing support for infants suffering from Respiratory Distress Syndrome (RDS) in non-NICU settings. It is the world’s first CPAP device with a manual powering option, and is designed to work during transport as well as secondary care settings.The Saans device features an in-built compressor and blender, battery backup for up to 4-6 hours, and compatibility with all standard oxygen sources and patient interfaces, making it a versatile breathing support system for children. The device was conceptualized and developed in partnership with the Consortium for Affordable Medical Technologies (CAMTech) and the Department of Biotechnology, Government of India.